Curanex Pharmaceuticals INC 8-K filings

Curanex Pharmaceuticals provided a Q1 2026 business update, highlighting advancements in its lead drug candidate Phyto-N for ulcerative colitis and expansion into cancer cachexia.

Curanex Pharmaceuticals has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, now until November 2, 2026.

Curanex Pharmaceuticals is expanding its drug development pipeline to include cancer cachexia, targeting a multi-billion-dollar market opportunity.

Curanex Pharmaceuticals Inc. has entered into new employment agreements with its CEO, Jun Liu, and COO, Dr. Liqin Xie, formalizing their compensation and responsibilities.

Curanex Pharmaceuticals Inc. announced the resignation of CFO Haiyan Yang and the appointment of Wanjun Zhang, effective January 1, 2026.

Curanex Pharmaceuticals Inc. received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Curanex Pharmaceuticals Inc. issued shares to an investor and fully repaid $400,000 in loans from an executive's spouse, eliminating all outstanding debt.

Curanex Pharmaceuticals Inc. announced underwriters fully exercised their over-allotment option, raising an additional $2.25 million in gross proceeds from its IPO.

Curanex Pharmaceuticals Inc. successfully closed its initial public offering, raising $15 million in gross proceeds to advance its botanical drug pipeline for inflammatory diseases.

Curanex Pharmaceuticals Inc. announced the pricing of its initial public offering of 3.75 million shares at $4.00 per share, raising $15 million in gross proceeds.